Trial intelligence / Profile preview

Avapritinib in Unresectable or Metastatic GIST (China, Phase I/II)

CTR20191409Phase 2Completed

Sponsor
Blueprint Medicines
Start
Jul 2019
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
Countries
1
01

Overview

A Phase 2 trial of avapritinib in gastrointestinal stromal tumor (GIST), sponsored by Blueprint Medicines. Started Jul 2019; status: completed.

02

Drugs

avapritinib
03

Conditions

gastrointestinal stromal tumor (GIST)

Beyond the preview

Go deeper on CTR20191409.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on CTR20191409.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call